Specialized Canagliflozin Compositions for Niche Environments

Publication ID: 24-11857559_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Canagliflozin Compositions for Niche Environments,” Published Technical Disclosure No. 24-11857559_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857559_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,559.

Summary of the Inventive Concept

The present inventive concept relates to specialized pharmaceutical compositions of Canagliflozin adapted for specific, narrow markets or unique operational environments, such as high-security needs, disaster relief, or extreme weather conditions.

Background and Problem Solved

The original patent disclosed a stable pharmaceutical composition of Canagliflozin, but it has limitations in terms of its applicability in niche environments. The present inventive concept addresses these limitations by providing specialized compositions that can withstand extreme temperature fluctuations, high-humidity environments, and other challenging conditions.

Detailed Description of the Inventive Concept

The new inventive concept comprises a system for delivering Canagliflozin in high-altitude environments, a method for treating patients in disaster relief zones, a pharmaceutical composition for use in extreme weather conditions, a system for securing pharmaceutical compositions in high-security environments, and a method for treating patients in remote or isolated areas. These specialized compositions are formulated to be stable in challenging environments and provide a reliable treatment option for patients in need.

Novelty and Inventive Step

The new inventive concept provides a novel and non-obvious solution by adapting the original composition to specific niche environments, thereby expanding its applicability and value. The inventive step lies in the recognition of the need for specialized compositions and the development of formulations that can withstand extreme conditions.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include compositions adapted for use in space exploration, military operations, or other unique environments. Variations of the composition could include different ratios of excipients, alternative coating materials, or modified manufacturing processes.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of disaster relief, extreme weather response, and high-security environments. The target market includes government agencies, non-profit organizations, and private companies operating in these niches.

Field of Art

Pharmaceutical formulation and drug delivery systems, specifically focused on SGLT2 inhibitor compositions with emphasis on stability, excipient interactions, and environmental adaptability

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical formulation scientist with expertise in drug stability, excipient selection, coating technologies, and environmental adaptation strategies for pharmaceutical compositions, typically holding a PhD or equivalent industrial experience in pharmaceutical sciences

Obviousness Rationale

A PHOSITA would recognize that the source patent's foundational composition of amorphous canagliflozin with specific excipients provides a predictable template for environmental adaptation. The disclosed variations represent routine engineering modifications to extend the composition's utility across different operational contexts. The core formulation strategy remains consistent, with minor adjustments to address specific environmental challenges.

Obvious Combinations & Variations

Source Patent Element
Stable amorphous canagliflozin composition with defined excipient ratios
PTD Variation
Adaptation of composition for high-altitude or extreme temperature environments
Obviousness Reasoning
Predictable modification using known excipient selection techniques to enhance thermal and environmental stability, representing a standard pharmaceutical engineering approach
Source Patent Element
Pharmaceutical composition with moisture-sensitive active ingredient
PTD Variation
Addition of moisture-resistant coating to protect composition in high-humidity environments
Obviousness Reasoning
Known protective strategy in pharmaceutical formulation to mitigate moisture-related degradation, utilizing standard coating technologies
Source Patent Element
Pharmaceutical composition with defined stability parameters
PTD Variation
Extended stability testing for 12 months without refrigeration in remote environments
Obviousness Reasoning
Routine stability investigation representing standard pharmaceutical development practice to explore composition performance under varied storage conditions
Source Patent Element
Pharmaceutical composition with defined excipient interactions
PTD Variation
Specialized formulation for high-security or disaster relief environments
Obviousness Reasoning
Predictable application of existing formulation knowledge to address specific contextual requirements through minor compositional adjustments
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857559, a person having ordinary skill in the art would find the variations disclosed in the Published Technical Disclosure to represent obvious extensions of the foundational pharmaceutical composition, utilizing standard pharmaceutical engineering techniques to adapt the composition for specific environmental contexts without requiring inventive insight beyond routine formulation development practices.

Original Patent Information

Patent NumberUS 11,857,559
TitlePharmaceutical composition comprising Canagliflozin, process of preparation and use thereof
Assignee(s)Aurobindo Pharma Ltd